Cargando…
Renin-angiotensin system inhibition in COVID-19 patients
Angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and angiotensin II type‑1 receptor blockers (ARBs) are among the most widely prescribed drugs for the treatment of arterial hypertension, heart failure and chronic kidney disease. A number of studies, mainly in animals and not involving the lung...
Autor principal: | de Vries, A. A. F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278773/ https://www.ncbi.nlm.nih.gov/pubmed/32514935 http://dx.doi.org/10.1007/s12471-020-01439-5 |
Ejemplares similares
-
Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic
por: Katsiki, Niki, et al.
Publicado: (2020) -
Return to sports after COVID-19: a position paper from the Dutch Sports Cardiology Section of the Netherlands Society of Cardiology
por: Verwoert, G. C., et al.
Publicado: (2020) -
Telerehabilitation in the Age of COVID-19: An Opportunity for Learning Health System Research
por: Prvu Bettger, Janet, et al.
Publicado: (2020) -
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
por: Klamer, T. A., et al.
Publicado: (2022) -
Recommendations on how to provide cardiac rehabilitation services during the COVID-19 pandemic
por: Kemps, H. M. C., et al.
Publicado: (2020)